Swedish Orphan Biovitrum AB (publ) announced that the first patients have been enrolled in the A-SURE study (NCT02976753). A-SURE is a 24-month real-world study evaluating the effectiveness of Elocta® compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A in Europe. The efficacy and safety of Elocta have been established in clinical trials and the A-SURE study will provide data from a real-world setting, which can be made available to physicians, payers and reimbursement authorities in evaluating the effectiveness and usage of Elocta. The A-SURE study plans to enroll 350 patients in around 10 countries in Europe.